Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation

I V Smirnova1, M Kajstura, T Sawamura

  • 1Department of Medicine, New York Medical College, Valhalla, NY 10595, USA.

Insights

Nitric oxide (NO) deficiency, caused by elevated asymmetric dimethylarginine (ADMA), promotes macrophage lipid accumulation by upregulating the lectin-like oxidized LDL receptor (LOX-1). This NO deficiency contributes to foam cell formation, a key step in atherosclerosis.

Area of Science:

  • Cardiovascular Research
  • Atherosclerosis Pathogenesis
  • Molecular Biology

Background:

  • Elevated asymmetric dimethylarginine (ADMA) is linked to cardiovascular diseases.
  • ADMA inhibits nitric oxide synthase (NOS), leading to NO deficiency.
  • Macrophage lipid accumulation is a critical step in atherogenesis.

Purpose of the Study:

  • To investigate the role of NO deficiency in macrophage lipid accumulation.
  • To determine if NO deficiency contributes to the development of foam cells.

Main Methods:

  • Inhibition of NO synthesis in human monocytic leukemia HL-60 cells.
  • Treatment of activated macrophages with ADMA or N(G)-nitro-l-arginine methyl ester (l-NAME).
  • Assessment of oxidized LDL (OxLDL) receptor (LOX-1) expression and DiI-OxLDL uptake.
  • Gene silencing of LOX-1 using small interfering RNA (siRNA).

Main Results:

  • Inhibition of NO synthesis increased LOX-1 expression and DiI-OxLDL accumulation in macrophages.
  • ADMA and l-NAME treatment led to increased lipid staining and foamy appearance in macrophages.
  • LOX-1 gene silencing reduced OxLDL uptake and lipid accumulation.

Conclusions:

  • NO deficiency, potentially due to ADMA accumulation in chronic renal failure, upregulates LOX-1.
  • Increased LOX-1 facilitates OxLDL uptake, contributing to macrophage lipidosis and foam cell formation.
  • NO exerts a non-endothelial antiatherogenic effect by preventing LOX-1 induction and macrophage lipid accumulation.